In conclusion, PNO1 can be used as a diagnostic biomarker for lung adenocarcinoma, and inhibition of PNO1 by CRISPR/Cas9 technology can be a useful strategy for the treatment of lung adenocarcinoma. The gene discussed is PNO1; the disease is lung adenocarcinoma.